


Pharma AI

Index Hedge Fund for AI in Drug Discovery



Pharma AI Index Hedge Fund

A Specialised Index Hedge Fund for the AI in Drug Discovery Sector



Combines the profitability of venture funds with the liquidity of hedge funds



Invests in the Top 25 Companies in the AI for Drug Discovery Sector



Significantly De-risks the Interests of LP's



Bets on the success of the entire industry, rather than the success of individual companies

Core Components of Pharma AI Index Hedge Fund


Deep Pharma Intelligence and Analysis of the Industry Sector

Investment Strategy and Tactics / Structuring of Portfolio and Positions in AI for Drug Discovery Companies

Actively Managing, De-Risking and Systematic Optimization of Portfolio

Deploying Index of AI for Drug Discovery Industry

Enabling Options of Liquid Positions for Investors into Fund and Index



Deep Pharma Intelligence

Proprietary technologies of Deep Knowledge Ventures based on specialized advanced market research and comparative analysis frameworks of Deep Knowledge Analytics, to serve as the fundament for the fund's investment target identification and due diligence processes.

Investment Strategy and Tactics / Structuring of Portfolio and Positions in AI for Drug Discovery Companies.

Deep Knowledge Ventures' proprietary technologies relating to optimized portfolio structuring and positioning to build harmonized and synergetic portfolio organization, as well as ongoing, active and dynamic portfolio restructuring over time.

Actively Managing, De-Risking and Systematic Optimization of Portfolio.

Deep Knowledge Ventures in coordination with Deep Knowledge Analytics will use sophisticated comparative analytics frameworks and market research to actively manage the fund, structuring its initial composition and periodically re-tuning it in response to market events and conditions, to achieve an optimized balance in terms of portfolio structure in real-time.

Deploying Index of AI for Drug Discovery Industry.

Once the portfolio is structured, upon reaching a critical mass of managed capital, the fund will seek to become an exchange traded fund (ETF), capable of being traded on OTC trading platforms, as part of the next stage in the evolution of the fund. We are currently in discussions with several leading Swiss banks and OTC trading platforms in order to facilitate this process.

Enabling Options of Liquid Positions for Investors into Fund and Index.


The use of specialized financial instruments and hybrid investment technologies certified by third-party financial institutions to provide LPs with enhanced liquidity to overcome the liquidity issues faced by traditional venture capital firms, thereby combining the profitability of VC firms with the liquidity of hedge funds.

Landscape of the AI in Pharma Industry

In 2015, our group (i.e., **Deep Knowledge Ventures** and its analytics arm, **Deep Knowledge Analytics**) began to understand the complexities, challenges and opportunities of this entire sector, including both the industry landscape itself, as well as the unique issues posed by it to investment funds and their LPs, having made our first investment in this sector in 2015, long before the real dynamic of development was apparent to investors.

Since then, we have produced thousands of pages worth of reports offering deep industry intelligence on this sector, with more than four industry analytical reports on the topic under our belt to date.

Companies	-	125
Investors	-	260
Corporations	-	30



Deep Knowledge Analytics

The Analytical Fundament Behind the Fund's Investment Strategy and Tactics

Deep Knowledge Analytics, the analytical arm of **Deep Knowledge Ventures**, has released a new analytical report on the Artificial Intelligence in Drug Discovery (DD) sector each quarter for more than one year. It was the process of cultivating this **deep expertise** in the AI in DD industry, including its strengths, weaknesses, disproportions, challenges and opportunities, that motivated us to develop and launch the Pharma AI fund, managed by Deep Knowledge Ventures, in order to seize the untapped opportunity of making active investments into this sphere in a targeted manner. **Having been the first investor into Insilico Medicine (one of the current leaders of the AI in Drug Discovery sector) in 2014**, years before the AI in DD industry rose to its current level of prominence, we have a practical appreciation for the kinds of due diligence necessary to separate the weaker players from the strong ones in the industry, and of the **precise metrics** and **parameters** required to form **clear-cut analyses** of which companies are **over-valuated**, **under-valuated** and **fairly valuated**.



AI for Drug Discovery Landscape Overview 2017

www.dkv.global



ANALYTICAL REPORT SAMPLE

**AI FOR
DRUG DISCOVERY,
BIOMARKER DEVELOPMENT
AND ADVANCED R&D
LANDSCAPE OVERVIEW
2018 / Q1**

**Companies - 80
Investors - 180
Corporations - 25
R&D Centers - 20**

www.analytics.dkv.global

Timeline 2019

